Seer Enters Into a Co-Marketing and Sales Agreement With Thermo Fisher Scientific
Complete the form below to unlock access to ALL audio articles.
Seer, Inc. (Nasdaq: SEER), announced a co-marketing and sales agreement with Thermo Fisher Scientific, the world leader in serving science, to jointly promote Seer’s Proteograph™ Product Suite alongside Thermo Scientific Orbitrap Astral™ mass spectrometers. This strategic collaboration aims to accelerate the adoption of innovative proteomic technologies, offering researchers an integrated solution for deep, rapid, and unbiased proteomic analysis at scale.
Under this non-exclusive agreement, Thermo Fisher’s global sales force will have the ability to quote and sell Seer’s Proteograph Product Suite, which includes an automation instrument, proprietary engineered nanoparticles, and software analysis suite, enhancing the accessibility of this innovative technology to life science researchers worldwide. The integration is set to commence in early 2025, further expanding the reach of Seer’s platform. The collaboration will also enable Seer and Thermo Fisher to conduct joint marketing activities, including conference promotions, seminars, and webinars, to showcase the combined power of their proteomic platforms.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREE“This collaboration represents a pivotal step in our mission to transform proteomics by integrating our Proteograph Product Suite with Thermo Fisher’s Orbitrap Astral mass spectrometers,” said Omid Farokhzad, CEO and Chair of Seer. “Thermo Fisher mass spectrometers set the gold standard for proteomics. By enabling Thermo Fisher customers to acquire the Proteograph Product Suite in conjunction with an Orbitrap Astral, we are expanding access to these powerful tools and setting a new standard in proteomics that has the potential to accelerate scientific discoveries and ultimately improve human health.”
The companies will work together to improve workflows, creating a seamless sample-to-data experience that integrates the Proteograph and Astral technologies. The combination of the Proteograph Product Suite and Orbitrap Astral has generated exciting data for academic and commercial customers. Seer and Thermo Fisher plan to collaborate on additional joint research studies, including population scale studies, to demonstrate the comprehensive capabilities of their combined platforms, further solidifying their commitment to advancing the field of proteomics.
“This agreement builds on our existing partnership with Seer and represents a strong advancement in accelerating innovation in proteomics,” said John Lesica, President, Chromatography and Mass Spectrometry, Thermo Fisher Scientific. “By aligning our technologies, we are providing our customers with a scalable end-to-end solution to enable comprehensive proteomic insights, ultimately driving breakthroughs in understanding human biology and disease.”